APP and Alzheimer disease: Therefore, transgenic models of Aβ pathology have been developed that overexpress human APP (hAPP) with AD‐associated mutations which favour the amyloidogenic β‐secretase pathway of APP processing (Games et al., 1995; Hsiao et al., 1996; Sturchler‐Pierrat et al., 1997).